Accepted answer
98.4 and 96.4 are 2 percentage points apart, which sounds small until you restate it as impurity. VendorInvestigate is leaving 1.6 per cent of the detected area unassigned and Janoshik 3.6 per cent — a factor of 2.25 between them. The impurity fraction is the quantity that moves when a method changes, and it is the one worth arguing about; the headline is just its complement. Comparable means same column chemistry, same gradient slope, same detection wavelength, same integration convention. Until you have those four from both laboratories, 98.4 and 96.4 are two measurements of slightly different quantities that happen to share a unit.
Understanding purity requires separating the chemistry from the method from the reporting convention, and the three are not independent.
Mobile phase additive choice affects ionisation and peak shape — TFA gives sharp peaks but suppresses mass spectrometry signal, formic acid gives worse peaks but preserves signal.
Detection wavelength matters because 214 nm sees the peptide backbone while 280 nm sees only aromatic side chains — so truncation impurities lacking a tryptophan are invisible at 280 nm.
The ICH Q3A impurity thresholds and the relevant pharmacopoeial chapters all specify method validation requirements that almost no research-grade certificate claims to meet.
If you are ranking vendors, specify a method and have all samples tested at the same place.
edited 27 Jan 2025 by gradient_slope — updated for the 2026 guidance change
The system-suitability data is the part that tells you whether to believe the rest. – jo_vandeberg 3 months ago Adding a vote because this deserves more of them. – Dr_Aoife_Brennan 5 months ago add a comment